VeriStrat is a serum proteomic test that predicts response to a specific targeted therapy, erlotinib, in patients with advanced NSCLC. Identifying patients likely to benefit from erlotinib helps physicians personalize therapy and may improve patient outcomes. Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1500 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other targeted therapies. For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. In 2009, Biodesix launched VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient's condition or likely outcome in response to therapy. The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies. For more information about Biodesix, please visit the Company's website
|SOURCE Biodesix Inc.|
Copyright©2010 PR Newswire.
All rights reserved